Platelet responses in individual patients in a phase 1/2 dose escalation study of rozrolimupab. Dashed lines represent patients who received rescue medications during the study. See Figure 1A in the article by Robak et al that begins on page 3670.
Platelet responses in individual patients in a phase 1/2 dose escalation study of rozrolimupab. Dashed lines represent patients who received rescue medications during the study. See Figure 1A in the article by Robak et al that begins on page 3670.
